SELLAS Life Sciences Group
D

SLS

11.350
USD
-0.19
(-1.60%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-52
حجم السوق
2,292,083,797
أصول ذات صلة

العنوان: SELLAS Life Sciences Group

القطاع: الرعاية الصحية
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.